Ascentage Pharma to Showcase 17 Clinical Advances at EHA2026
Ascentage Pharma will present 17 clinical advances—eight via poster—at EHA2026 in Stockholm June 11–14. Presentations include updated efficacy and safety data for Olverembatinib (HQP1351) in chronic-phase CML and preliminary results for Lisaftoclax (APG-2575) in CLL/SLL.
1. Conference Presentation Overview
Ascentage Pharma will feature 17 abstracts at the 31st Congress of the European Hematology Association in Stockholm June 11–14, including eight poster presentations showcasing its core assets Olverembatinib and Lisaftoclax.
2. Olverembatinib Clinical Updates
Key abstracts detail updated efficacy and safety of Olverembatinib (HQP1351) as second-line therapy in chronic-phase CML, efficacy in patients with prior resistance to Ponatinib or Asciminib and ASXL1 mutations, and results from the global Phase 3 POLARIS-1 trial in newly diagnosed Ph+ ALL.
3. Lisaftoclax Study Highlights
Presentations also cover correlation of baseline characteristics with prognosis in CLL/SLL patients treated with Lisaftoclax (APG-2575) from a pivotal Phase 2 study, as well as safety and preliminary efficacy of combined Olverembatinib and Lisaftoclax in pediatric relapsed/refractory Ph+ ALL.